Business Context and Reporting Period
Company: PowerVerde, Inc. (formerly Vyrex Corporation)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Status: Development Stage Company. The entity focuses on renewable power systems for natural gas pipeline operations following a 2008 merger. It has no employees as of the report date and relies on outsourcing manufacturing to Arizona Research and Development (ARD). The company has a history of recurring operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 | Cumulative (Inception to Mar 31, 2009) |
|---|---|---|---|
| Revenue (Licensing & Royalty) | $3,384 | $11,063 | $27,047 |
| Net Loss | $(194,093) | $(149,126) | $(1,298,051) |
| Cash and Equivalents (End of Period) | $98,372 | $92,176 | N/A |
| Working Capital Deficit | $(392,331) | N/A | N/A |
| Total Debt (Notes Payable) | $211,955 | $136,959 | N/A |
| Accounts Payable | $282,132 | $214,750 | N/A |
| Stockholders' Deficiency | $(383,134) | $(329,041) | N/A |
Operating Expenses: Total operating expenses for Q1 2009 were $115,336, comprised of $72,493 in Research and Development and $42,843 in General and Administrative costs.
Interest Expense: $82,141 for Q1 2009, primarily driven by the amortization of discounts on notes payable ($74,996).
Material Changes vs. Prior Period
- Revenue Decline: Licensing revenue decreased by approximately 69% from $11,063 in Q1 2008 to $3,384 in Q1 2009.
- Increased Loss: Net loss increased by 30% to $194,093 in Q1 2009 compared to $149,126 in Q1 2008, largely due to significant non-cash interest expense from warrant amortization.
- Debt Increase: Notes payable increased by $74,996 (from $136,959 to $211,955) due to the amortization of the discount on Series A Promissory Notes.
- Cash Position: Cash and cash equivalents increased significantly from $10,203 at year-end 2008 to $98,372 at March 31, 2009, driven by financing activities.
- Equity Issuance: The company issued 333,333 shares of common stock in March 2009 at $0.75 per share, raising $250,000 (with $165,000 received by quarter-end).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management states that substantial net losses will continue unless products are successfully commercialized. The company plans to mass-produce patented renewable power systems using outsourced manufacturing (ARD) and intends to hire sales staff by the end of Q3 2009. Beta testing is expected to conclude by the end of Q3 2009.
Liquidity and Capital Resources
The company faces a critical liquidity situation. It must raise substantial additional capital to finance operations and repay $250,000 in Series A Notes due July 31, 2009. Management intends to negotiate a conversion of these notes to equity. Failure to raise funds or convert debt could force the company to cease operations.
Risks and Contingencies
- Going Concern: The financial statements include a "Going Concern" warning due to recurring losses and negative cash flows.
- Internal Controls: Disclosure controls and procedures were deemed not effective as of March 31, 2009, necessitating a restatement of the Q3 2008 financials regarding warrant valuation.
- Market Conditions: Capital raising efforts have been hampered by the global financial crisis and recession.
Unusual Items
Interest expense of $82,141 includes $74,996 of non-cash amortization of debt discounts related to warrants issued with Series A Notes and a line of credit. The company also assigned its Biotech IP to an investor in March 2009 in exchange for the assumption of future expenses and a 20% royalty on future proceeds.
Investor Verification Checklist
- Debt Maturity: Verify the status of the $250,000 Series A Notes due July 31, 2009, and the likelihood of conversion to equity.
- Cash Burn Rate: Assess if the current cash balance ($98,372) is sufficient to cover operating expenses until the next funding round or commercialization.
- Restatement Impact: Review the amended 10-Q for the quarter ended September 30, 2008, to understand the full impact of the warrant valuation restatement.
- Manufacturing Agreements: Confirm the execution of the manufacturing agreement with Arizona Research and Development (ARD) and the timeline for beta testing completion.
- Warrant Liability: Monitor the outstanding 490,000 warrants and their potential dilution impact if exercised.